Compare Nutrien Ltd (NTR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs TG Therapeutics Inc — how do they compare? Nutrien Ltd trades at $66.8 (market cap $31.67B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Nutrien Ltd is far larger — about 3.8× TG Therapeutics Inc's market cap, and Nutrien Ltd pays a 3.3% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NTR | TGTX | |
|---|---|---|
Market Cap | $31.67B | $8.26B |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $59.06 |
52-Week Low | $53.64 | $26.39 |
Enterprise Value | $44.84B | $8.50B |
Dividend Yield | 3.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $66.84, down 0.65% with neutral technical signals. The company shows improving fundamentals with Q1 2026 earnings beat and projected revenue growth to $27.8B in 2026. Valuation appears reasonable with P/E of 13.58 and P/S of 1.16. Recent institutional buying activity and a $0.55 dividend payment scheduled for July 2026 provide additional investor appeal.
The outlook remains positive with strong analyst consensus (60.6% buy ratings) and $77.67 price target suggesting 16% upside. Key risks include volatile input costs and fertilizer market dynamics. The combination of reasonable valuation, earnings momentum, and institutional support positions NTR favorably for long-term investors despite near-term market volatility.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
